Clinical Trial Update: A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for WX390 in patients with PIK3CA mutation-related tumors across Phase 1 and Phase 2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca Mutation-related Tumors

Drugs mentioned

• WX390

Snippet

Sponsor: Shanghai Jiatan Pharmatech Co., Ltd | Conditions: PIK3CA Mutation-Related Tumors | Phase 1, Phase 2 | Status: COMPLETED